Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs
Ex-Novartis chief Joe Jimenez and his longtime colleague Mark Fishman have now ramped up their 5th biotech sub at the upstart Aditum. And once again, they’re tackling a big, tough market.
The new outfit is called Ancora Bio, and its drug is a selective vasopressin 1b receptor — V1b — antagonist from Taisho Pharmaceutical that will roll ahead under a new code name: ANC-501.
Evidently this is the same depression drug that Taisho tested in a recent Phase II clinical study. Some numbers trended in its favor compared to a placebo but fell short of statistical significance — just one in a long series of failures for major depression.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.